Get the Stockscreener App
2.98
18.73%
0.47
Yd Bio Ltd stock is traded at $2.98, with a volume of 73,475.
It is up +18.73% in the last 24 hours and up +40.57% over the past month.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.
See More
Previous Close:
$2.51
Open:
$2.76
24h Volume:
73,475
Relative Volume:
0.58
Market Cap:
$211.08M
Revenue:
-
Net Income/Loss:
$-2.97M
P/E Ratio:
-3.0162
EPS:
-0.988
Net Cash Flow:
$-1.18M
1W Performance:
+29.85%
1M Performance:
+40.57%
6M Performance:
-69.72%
1Y Performance:
+0.00%
1-Day Range:
$2.415
$3.2399
1-Week Range:
$2.1701
$3.2399
52-Week Range:
$1.70
$25.00
Yd Bio Ltd Stock (YDES) Company Profile
Compare YDES vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
YDES
Yd Bio Ltd
|
2.98 | 184.16M | 0 | -2.97M | -1.18M | -0.988 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Yd Bio Ltd Stock (YDES) Latest News
YD Bio Ord Shs (YDES) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
YD Bio launches nutrition products via physician partnership model By Investing.com - Investing.com South Africa
YD Bio launches nutrition products via physician partnership model - Investing.com
YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute - Yahoo Finance
YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research - Yahoo Finance
Keratoconus Study Ranks Molecules for Future Corneal Therapy Research - Stock Titan
YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada - The Manila Times
YD Bio launches pilot for cancer testing in British Columbia By Investing.com - Investing.com Canada
Five Cancer Types Targeted in YD Bio's Cross-Border Pilot - Stock Titan
Y.D. More group (TATT) reports 5.42% beneficial stake in TAT Technologies - Stock Titan
YD Bio Ord Shs (YDES) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
YD Bio launches pilot for cancer testing in British Columbia - Investing.com
YD Bio Ord Shs (YDES) Cash Flow - TradingKey
YDES|YD Bio Ord Shs|Price:2.350|Chg%:+0.110 - TradingKey
YD Bio Ord Shs (YDES) Balance Sheet - TradingKey
YDES|YD Bio Ord Shs|Price:2.300|Chg%:-0.020 - TradingKey
YD Bio Ord Shs (YDES) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
YD Bio Ord Shs (YDES) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
YD Bio Ord Shs (YDES) Institutional Confidence - TradingKey
YD Bio Ord Shs (YDES) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
YD Bio Ord Shs (YDES) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
YDES|YD Bio Ord Shs|Price:2.240|Chg%:+0.200 - TradingKey
YD Bio Ord Shs (YDES) Income Statement - TradingKey
YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services - The Manila Times
30 Prospective Partners Explore Cancer Tests and Eye Care at Taiwan Expo - Stock Titan
Diabetic Macular Edema Pipeline 2026: MOA, ROA, FDA-Approved - openPR.com
Gapping stocks in Wednesday's session - ChartMill
Enterprise value to revenue forward of YD Bio Limited – NASDAQ:YDES - TradingView
PLPC Q1 2026 Earnings: EPS Surprises to the Upside, but Stock DeclinesAnnual Report - dars.gov.et
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Which stocks have an unusual volume on Tuesday? - ChartMill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
YD Bio (YDESW) Stock Analysis Report | Financials & Insights - Benzinga España
YD Bio affiliate obtains lab licenses in Rhode Island, Pennsylvania - Investing.com
YD Bio affiliate obtains lab licenses in Rhode Island, Pennsylvania By Investing.com - Investing.com Canada
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations - Yahoo Finance
Yidu Tech Achieves Its First Full-Year Profit: FY2026 Net Profit Reaches RMB 78.8 Million, with Positive Operating Cash Flow in the Second Half - Yahoo Finance
RSU grant and exercise update for YD Bio (YDES) director Lu - Stock Titan
RSU grant and exercise for YD Bio (YDES) director Chang Kochi - Stock Titan
YD Bio Ltd (NASDAQ: YDES) Share Price, YDES Stock News, YDES Share Price & Updates - Kalkine
MegaGen and BIOLASE Invest Nearly $1 Million to Expand Manufacturing Infrastructure at Corona, California Facility - Yahoo Finance
Morning Market Movers: CUPR, BNC, ABSI, WEN See Big Swings - RTTNews
BRZHR Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
YD Bio Ord Shs (YDES) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
YD Bio Ord Shs (YDES) Valuation: PE, PB & Fair Value Analysis - TradingKey
Morning Market Movers: SLBT, SCLX, TDIC, CRE See Big Swings - RTTNews
FOCL Stock Price and Chart — NASDAQ:FOCL - TradingView
[EFFECT] YD Bio Ltd SEC Filing - Stock Titan
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview - Yahoo Finance
Saga Communications (SGA) Drops 4.3%: Support Levels in Focus After Recent DeclineDescending Triangle - dars.gov.et
Yd Bio Ltd Stock (YDES) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):